Payment overview · 2025
General Payments
$870.15
47 reported records · 18 companies
Healthcare provider profile · identity verified
Robert James Wielenga, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DOWNEY, CA · NPI 1952469850
Verified facts
What the public records show
CMS Open Payments records show Robert James Wielenga, M.D. received $870.15 in general payments during 2025 across 47 reported records.
Radius Health, Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Prolia, Trintellix, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 371 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Tymlos by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $192.51 | 22.1% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $109.48 | 12.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $93.36 | 10.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $85.25 | 9.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.24 | 8.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.82 | 4.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.06 | 4.3% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $35.10 | 4.0% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $30.50 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.75 | 2.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.02 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.06 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.60 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.46 | 2.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.81 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.09 | 2.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.91 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.13 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $870.15 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $192.51 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $93.36 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $85.25 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.26 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.54 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.43 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $30.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 132 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 252 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 371 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 118 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
118 | 80 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
138 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
252 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
143 | 32 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
371 | 79 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 36 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1337 | 432 |
| Amlodipine Besylate | Amlodipine Besylate | 1022 | 314 |
| Losartan Potassium | Losartan Potassium | 981 | 309 |
| Levothyroxine Sodium | Levothyroxine Sodium | 920 | 273 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 648 | 201 |
| Metformin Hcl | Metformin Hcl | 645 | 210 |
| Escitalopram Oxalate | Escitalopram Oxalate | 554 | 195 |
| Tamsulosin Hcl | Tamsulosin Hcl | 551 | 180 |
| Gabapentin | Gabapentin | 541 | 217 |
| Pantoprazole Sodium | Pantoprazole Sodium | 530 | 200 |
| Metoprolol Succinate | Metoprolol Succinate | 501 | 151 |
| Memantine Hcl | Memantine Hcl | 492 | 135 |
| Alendronate Sodium | Alendronate Sodium | 463 | 163 |
| Alprazolam | Alprazolam | 459 | 131 |
| Furosemide | Furosemide | 420 | 133 |
| Fluticasone Propionate | Fluticasone Propionate | 391 | 184 |
| Lisinopril | Lisinopril | 385 | 118 |
| Ozempic | Semaglutide | 371 | 79 |
| Omeprazole | Omeprazole | 347 | 112 |
| Lansoprazole | Lansoprazole | 342 | 111 |
| Glipizide | Glipizide | 338 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 297 | 117 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 97 |
| Potassium Chloride | Potassium Chloride | 272 | 79 |
| Carvedilol | Carvedilol | 271 | 84 |
| Naproxen | Naproxen | 271 | 83 |
| Famotidine | Famotidine | 258 | 97 |
| Jardiance | Empagliflozin | 252 | 69 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 246 | 130 |
| Finasteride | Finasteride | 239 | 80 |
| Trazodone Hcl | Trazodone Hcl | 239 | 75 |
| Metformin Hcl Er | Metformin Hcl | 232 | 69 |
| Celecoxib | Celecoxib | 197 | 71 |
| Meclizine Hcl | Meclizine Hcl | 196 | 93 |
| Mirtazapine | Mirtazapine | 190 | 70 |
| Levofloxacin | Levofloxacin | 189 | 160 |
| Tramadol Hcl | Tramadol Hcl | 186 | 66 |
| Ibuprofen | Ibuprofen | 182 | 63 |
| Baclofen | Baclofen | 178 | 68 |
| Donepezil Hcl | Donepezil Hcl | 178 | 47 |
| Simvastatin | Simvastatin | 166 | 48 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 165 | 119 |
| Benazepril Hcl | Benazepril Hcl | 159 | 50 |
| Clonidine Hcl | Clonidine Hcl | 159 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 38 |
| Januvia | Sitagliptin Phosphate | 150 | 39 |
| Xarelto | Rivaroxaban | 150 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 33 |
| Trulicity | Dulaglutide | 143 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 138 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 137 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 137 | 51 |
| Azithromycin | Azithromycin | 136 | 121 |
| Lorazepam | Lorazepam | 136 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 45 |
| Eliquis | Apixaban | 132 | 46 |
| Prolia | Denosumab | 118 | 80 |
| Doxycycline Hyclate | Doxycycline Hyclate | 117 | 96 |
| Montelukast Sodium | Montelukast Sodium | 114 | 37 |
| Allopurinol | Allopurinol | 113 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 48 |
| Folic Acid | Folic Acid | 107 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 35 |
| Valsartan | Valsartan | 102 | 29 |
| Bupropion Xl | Bupropion Hcl | 97 | 30 |
| Cefuroxime | Cefuroxime Axetil | 96 | 88 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 40 |
| Pregabalin | Pregabalin | 89 | 25 |
| Rivastigmine | Rivastigmine | 87 | 25 |
| Fenofibrate | Fenofibrate,micronized | 86 | 26 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 85 | 39 |
| Ezetimibe | Ezetimibe | 84 | 36 |
| Atenolol | Atenolol | 79 | 26 |
| Fluconazole | Fluconazole | 77 | 51 |
| Icosapent Ethyl | Icosapent Ethyl | 77 | 28 |
| Sertraline Hcl | Sertraline Hcl | 75 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 25 |
| Nitroglycerin | Nitroglycerin | 71 | 45 |
| Prednisone | Prednisone | 71 | 42 |
| Temazepam | Temazepam | 70 | 12 |
| Lactulose | Lactulose | 68 | 29 |
| Nystatin | Nystatin | 67 | 21 |
| Methylprednisolone | Methylprednisolone | 66 | 51 |
| Vascepa | Icosapent Ethyl | 66 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 65 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 55 |
| Myrbetriq | Mirabegron | 62 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 23 |
| Buspirone Hcl | Buspirone Hcl | 61 | 16 |
| Glimepiride | Glimepiride | 59 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 57 | 16 |
| Primidone | Primidone | 56 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 15 |
| Hydrocortisone | Hydrocortisone | 53 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 48 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 21 |
| Repatha Sureclick | Evolocumab | 51 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 50 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 13 |
| Lovastatin | Lovastatin | 47 | 13 |
| Lubiprostone | Lubiprostone | 47 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 46 | 11 |
| Loperamide | Loperamide Hcl | 46 | 22 |
| Methocarbamol | Methocarbamol | 46 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | 16 |
| Amoxicillin | Amoxicillin | 45 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 44 | 18 |
| Ketoconazole | Ketoconazole | 43 | 24 |
| Repatha Pushtronex | Evolocumab | 43 | 21 |
| Linzess | Linaclotide | 42 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 15 |
| Nifedipine Er | Nifedipine | 41 | 11 |
| Divalproex Sodium | Divalproex Sodium | 40 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 35 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 39 | 21 |
| Spironolactone | Spironolactone | 38 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 14 |
| Clonidine | Clonidine | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 33 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | 14 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | 12 |
| Fenofibrate | Fenofibrate | 34 | 11 |
| Farxiga | Dapagliflozin Propanediol | 33 | 11 |
| Levetiracetam | Levetiracetam | 33 | 13 |
| Synthroid | Levothyroxine Sodium | 33 | 12 |
| Tymlos | Abaloparatide | 32 | 12 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 11 |
| Dutasteride | Dutasteride | 31 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 29 | 12 |
| Megestrol Acetate | Megestrol Acetate | 29 | 15 |
| Meloxicam | Meloxicam | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 13 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 29 | 24 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 15 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Gemtesa | Vibegron | 26 | 11 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | 12 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fluocinonide | Fluocinonide | 24 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | 11 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 16 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Estradiol | Estradiol | 18 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $870.15 · 47 records | Radius Health, Inc. | ACCRUFER, AIRSUPRA, AREXVY, CONTRAVE, Cologuard Collection Kit, EDARBI, ELIQUIS, EVENITY, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, SHINGRIX, TRINTELLIX, TZIELD, Tymlos, VRAYLAR, XIFAXAN, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error